

29 June 2023 ASX Code: MXC

Results of Shareholder's General Meeting

LSE Code: MXC

N
tl
A
T
D
a

MGC Pharmaceuticals Ltd ('MGC Pharma' or **'the Company')** would like to announce the results from the Company's General Meeting of Shareholders held today, Thursday, 29 June 2023, in accordance with ASX Listing Rule 3.13.2.

The Company confirms that all motions put to the meeting were voted by poll, with all resolutions carried.

Details of the proxy voting and voting outcomes for all motions put to the meeting are set out in the attached report.

-Ends-

Authorised for release by the Company Secretary, for further information please contact:

MGC Pharmaceuticals Ltd

Roby Zomer CEO & Managing Director +61 8 6382 3390 info@mgcpharma.com.au

UK Brokers

Peterhouse Capital

Charles Goodfellow / Lucy Williams / Duncan Vasey +44 207 469 0930

cg@peterhousecap.com / lw@peterhousecap.com

UK IR/PR Advisers IFC Advisory

Graham Herring / Tim Metcalfe / Zach Cohen mgcpharma@investor-focus.co.uk

MGC Pharmaceuticals Ltd

Arron Canicais / Rowan Harland Joint Company Secretaries +61 8 6382 3390 info@mgcpharma.co.uk

UK Brokers

Oberon Capital

Aimee McCusker / Adam Pollock +44 203 179 5300

 $\frac{a imeemc cusker@oberon investments.com}{a dampollock@oberon investments.com}\\$

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based pharmaceutical company, focused on developing and supplying accessible and ethically produced plant inspired medicines, combining in-house research with innovative technologies, with the goal of finding or producing treatments to for unmet medical conditions.

The Company's founders and executives are key figures in the global pharmaceuticals industry and the core business strategy is to develop and supply high quality plant inspired medicines for the growing demand in the medical markets in Europe, North America and Australasia.

MGC Pharma has a robust development pipeline targeting two widespread medical conditions and has further products under development.

MGC Pharma has partnered with renowned institutions and academia to optimise the development of targeted plant inspired medicines, to be produced in the Company's EU-GMP Certified manufacturing facilities.

MGC Pharma has a growing patient base in Australia, the UK, Brazil, and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market.

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

Results of Meeting



The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Ratification of prior issue of Convertible Notes	Ordinary	543,593,510	52,165,169	37,026,148	56,764,036	580,723,818	52,165,169	56,764,036	Carried
		85.91%	8.24%	5.85%		91.76%	8.24%		
2A Ratification of prior issue of Options	Ordinary	368,387,517	51,696,443	37,190,024	56,722,261	405,681,701	51,696,443	56,722,261	Carried
		80.56%	11.31%	8.13%		88.70%	11.30%		
2B Ratification of prior issue of Options	Ordinary	348,372,588	104,852,239	37,016,684	23,754,734	385,493,432	104,852,239	23,754,734	Carried
		71.06%	21.39%	7.55%		78.62%	21.38%		
3 Ratification of prior issue of Shares	Ordinary	518,193,406	105,084,039	37,016,684	23,754,734	555,314,250	105,084,039	23,754,734	Carried
		78.49%	15.91%	5.60%		84.09%	15.91%		
4 Approval for Share Placement	Ordinary	644,519,843	106,724,952	37,466,684	3,337,384	682,090,687	106,724,952	3,337,384	Carried
		81.72%	13.53%	4.75%		86.47%	13.53%		

^{*} Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.